The surge in GLP-1 use coincides with a downturn in the nations obesity crisis
This instability undermines continuity of care and directly impacts outcomes
This analysis is part of the Gallup National Health and Well-Being Index
Abushanab D, Marquina C, Morton JI, et al
Exenatide, a synthetic version of exendin-4 produced industrially, was the first GLP-1RA approved for the market [exenatide twice daily (EX-BID)], followed by a long-acting formulation that improved the delivery system [exenatide once a week (EX-QW)]
Typical Retail Pricing Understanding Ro's pricing relative to standard retail: Wegovy Retail Pricing (without insurance or savings): Typical Retail : $1,300-$1,400+ per month Ro Cash-Pay : $499/month via NovoCare Savings : ~$800-900/month (~64% reduction) Zepbound Retail Pricing (pens, without insurance): Typical Retail : $1,050-$1,100+ per month Ro Vials via LillyDirect : $349-$499/month Savings : ~$550-750/month (~66% reduction at maintenance dose) Important Context : Retail pricing represents list prices that few individuals pay
